Chengdang Xu

646 total citations
34 papers, 455 citations indexed

About

Chengdang Xu is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Cancer Research. According to data from OpenAlex, Chengdang Xu has authored 34 papers receiving a total of 455 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Pulmonary and Respiratory Medicine, 10 papers in Molecular Biology and 10 papers in Cancer Research. Recurrent topics in Chengdang Xu's work include Prostate Cancer Treatment and Research (14 papers), Cancer, Lipids, and Metabolism (5 papers) and Ferroptosis and cancer prognosis (5 papers). Chengdang Xu is often cited by papers focused on Prostate Cancer Treatment and Research (14 papers), Cancer, Lipids, and Metabolism (5 papers) and Ferroptosis and cancer prognosis (5 papers). Chengdang Xu collaborates with scholars based in China, United States and Canada. Chengdang Xu's co-authors include Denglong Wu, Wei Le, Zhendong Xiang, Gang Wu, Shengsong Huang, Xinan Wang, Bo Liu, Xi Chen, Junjie Ma and Yingna Chen and has published in prestigious journals such as SHILAP Revista de lepidopterología, Clinical Cancer Research and Frontiers in Immunology.

In The Last Decade

Chengdang Xu

34 papers receiving 451 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Chengdang Xu China 12 265 211 146 50 49 34 455
Rohaizak Muhammad Malaysia 11 157 0.6× 92 0.4× 47 0.3× 73 1.5× 43 0.9× 36 382
Yinlong Yang China 13 166 0.6× 108 0.5× 41 0.3× 61 1.2× 40 0.8× 35 513
Qiuyang Zhao China 8 154 0.6× 120 0.6× 63 0.4× 53 1.1× 7 0.1× 23 305
Haidan Yan China 14 315 1.2× 156 0.7× 112 0.8× 129 2.6× 8 0.2× 35 501
Petrea Hodge United States 3 266 1.0× 278 1.3× 523 3.6× 34 0.7× 16 0.3× 5 689
Wenhui Li China 10 117 0.4× 107 0.5× 60 0.4× 60 1.2× 15 0.3× 24 278
Xiyue Yang China 9 230 0.9× 158 0.7× 126 0.9× 52 1.0× 9 0.2× 23 380
Hongliang Wu China 12 207 0.8× 126 0.6× 93 0.6× 82 1.6× 13 0.3× 23 395

Countries citing papers authored by Chengdang Xu

Since Specialization
Citations

This map shows the geographic impact of Chengdang Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chengdang Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chengdang Xu more than expected).

Fields of papers citing papers by Chengdang Xu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chengdang Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chengdang Xu. The network helps show where Chengdang Xu may publish in the future.

Co-authorship network of co-authors of Chengdang Xu

This figure shows the co-authorship network connecting the top 25 collaborators of Chengdang Xu. A scholar is included among the top collaborators of Chengdang Xu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chengdang Xu. Chengdang Xu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wang, Xinan, Chengdang Xu, Junjie Ma, Xiao Wang, & Xi Chen. (2024). Identification of key genes participating in copper-diethyldithiocarbamate-related cell death process and predicting the development of prostate cancer. Discover Oncology. 15(1). 519–519. 1 indexed citations
2.
Wang, Xinan, Chengdang Xu, Xi Chen, et al.. (2024). PRL-mediated STAT5B/ARRB2 pathway promotes the progression of prostate cancer through the activation of MAPK signaling. Cell Death and Disease. 15(2). 128–128. 5 indexed citations
3.
Qin, Xin, Yan Zhao, Wei Jiang, et al.. (2024). Risk factor analysis and nomogram development for predicting 28-day mortality in elderly ICU patients with sepsis and type 2 diabetes mellitus. SHILAP Revista de lepidopterología. 22. 1 indexed citations
4.
Wang, Chenyang, Ying Liu, Xuyou Zhu, et al.. (2024). Perineural Invasion as a Risk Factor For Soft Tissue Progression in Patients With Metastatic Castration-Resistant Prostate Cancer After Abiraterone Resistance. Clinical Genitourinary Cancer. 22(5). 102125–102125. 1 indexed citations
5.
Xu, Chengdang, et al.. (2024). FGL2 as a predictive biomarker for prognosis and immunotherapy in bladder cancer. International Journal of Medical Sciences. 21(8). 1447–1460. 1 indexed citations
6.
Xu, Chengdang, Xinan Wang, Yiran Tao, et al.. (2023). Nucleophosmin 1 cooperates with BRD4 to facilitate c-Myc transcription to promote prostate cancer progression. Cell Death Discovery. 9(1). 392–392. 4 indexed citations
7.
Wu, Wei, Xinan Wang, Haopeng Li, et al.. (2023). Immune microenvironment infiltration landscape and immune-related subtypes in prostate cancer. Frontiers in Immunology. 13. 1001297–1001297. 24 indexed citations
8.
9.
Yang, Tao, Ying Liu, Yuanyuan Gao, et al.. (2022). Management of prostate cancer by targeting 3βHSD1 after enzalutamide and abiraterone treatment. Cell Reports Medicine. 3(5). 100608–100608. 18 indexed citations
10.
Liu, Ying, Tao Yang, Chengdang Xu, et al.. (2022). The clinical efficacy and limitations of dutasteride-regulated abiraterone metabolism in abiraterone-resistant patients: a prospective single-arm clinical trial in Chinese patients. Translational Andrology and Urology. 11(8). 1169–1176. 1 indexed citations
11.
Xu, Chengdang, et al.. (2022). Histone methyltransferase KMT2C plays an oncogenic role in prostate cancer. Journal of Cancer Research and Clinical Oncology. 148(7). 1627–1640. 4 indexed citations
12.
Chen, Xi, et al.. (2022). CCNB1 and AURKA are critical genes for prostate cancer progression and castration-resistant prostate cancer resistant to vinblastine. Frontiers in Endocrinology. 13. 1106175–1106175. 20 indexed citations
13.
Chen, Xi, et al.. (2022). CDK6 is upregulated and may be a potential therapeutic target in enzalutamide-resistant castration-resistant prostate cancer. European journal of medical research. 27(1). 105–105. 8 indexed citations
14.
Xiang, Zhendong, Pan Zhang, Qiang Wu, et al.. (2021). Histone acetyltransferase 1 upregulates androgen receptor expression to modulate CRPC cell resistance to enzalutamide. SHILAP Revista de lepidopterología. 11(7). e495–e495. 23 indexed citations
15.
Yang, Tao, Si Zhang, Yuanyuan Gao, et al.. (2021). Tracing steroidogenesis in prostate biopsy samples to unveil prostate tissue androgen metabolism characteristics and potential clinical application. The Journal of Steroid Biochemistry and Molecular Biology. 210(202). 105859–105859. 7 indexed citations
16.
Chen, Yingna, Chengdang Xu, Mengjiao Zhang, et al.. (2021). Quick identification of prostate cancer by wavelet transform-based photoacoustic power spectrum analysis. Photoacoustics. 25. 100327–100327. 12 indexed citations
17.
Chen, Yingna, Chengdang Xu, Anqi Zhu, et al.. (2021). Prostate cancer identification via photoacoustic spectroscopy and machine learning. Photoacoustics. 23. 100280–100280. 24 indexed citations
18.
Wu, Gang, Zhendong Xiang, Chengdang Xu, et al.. (2019). KDM5C is transcriptionally regulated by BRD4 and promotes castration-resistance prostate cancer cell proliferation by repressing PTEN. Biomedicine & Pharmacotherapy. 114. 108793–108793. 27 indexed citations
19.
Gao, Xiaomei, Charles S. Dai, Shengsong Huang, et al.. (2018). Functional Silencing of HSD17B2 in Prostate Cancer Promotes Disease Progression. Clinical Cancer Research. 25(4). 1291–1301. 41 indexed citations
20.
Huang, Shengsong, Yu Qin, Yingna Chen, et al.. (2018). Interstitial assessment of aggressive prostate cancer by physio‐chemical photoacoustics: An ex vivo study with intact human prostates. Medical Physics. 45(9). 4125–4132. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Rohaizak Muhammad Breakdown of academic impact, for papers by Yinlong Yang Breakdown of academic impact, for papers by Qiuyang Zhao Breakdown of academic impact, for papers by Haidan Yan Breakdown of academic impact, for papers by Petrea Hodge Breakdown of academic impact, for papers by Wenhui Li Breakdown of academic impact, for papers by Xiyue Yang Breakdown of academic impact, for papers by Hongliang Wu
Rankless by CCL
2026